Shares shifted as Nano-X Imaging, the Israeli medical-imaging company, slid 8.2% to $0.30 on a cascade of filings that laid bare a survival crisis. The maker of a low-cost digital X-ray system now trades at a market value of roughly $22 million — a fraction of the $2 billion investors assigned it at the end of 2020 — and faces a hard deadline to convince Nasdaq it still belongs on the exchange.
The Company Admits It May Not Survive the Next Twelve Months
Management said cash and deposits as of September 30, 2026 were insufficient to support operations for at least one year, raising "substantial doubt" about the company's ability to continue as a going concern. That language — required by auditing rules — is the corporate equivalent of a flashing red light. In Q1 alone Nanox burned $14 million in operating cash, and since its founding in 2012 it has accumulated a deficit of $463 million , funded almost entirely by selling stock. If the company cannot raise additional funds, it may delay, reduce, or eliminate product development.
A Drastic Reverse Split Shows How Far the Stock Has Fallen
Shareholders vote November 18 on adding 300 million authorized shares and approving a reverse-split framework that would consolidate every 20 to 50 shares into one. The goal: push the price above Nasdaq's $1.00 minimum. Nasdaq notified the company on September 28, 2026 that it was out of compliance; the initial 180-day cure period ends March 29, 2027. But reverse splits rarely fix what's broken — they shrink the share count without changing the business. Even if the split initially lifts the price, there is no assurance the company can sustain compliance over time.
Revenue Is Growing but Nowhere Near Fast Enough
Preliminary Q3 revenue came in at $4.3–$4.4 million, up year over year, driven by AI and software sales.
First-half 2026 revenue rose 45% to $8.5 million, but the company logged a $69.8 million net loss , illustrating the chasm between what Nanox earns and what it spends. At this pace, annual revenue would barely reach $17 million against quarterly cash burn in the mid-teens.
The CFO's Exit Adds Uncertainty at the Worst Time
CFO Guy Nathansohn requested to step down on October 26 citing medical reasons; the company said the departure was unrelated to any disagreement.
A successor search is underway. Losing a finance chief while negotiating survival-level capital raises leaves investors without a key voice at the table during the most precarious stretch in the company's history.